CTLA-4: New insights into its biological function and use in tumor immunotherapy

Nature Immunology

Volumn 3, Issue 7, 2002, Pages 611-618

  Egen, Jackson G ^a   Kuhns, Michael S ^a   Allison, James P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN FUNCTION; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL SURFACE; COLON CARCINOMA; CONTROLLED STUDY; CYTOLOGY; FIBROSARCOMA; HUMAN; IMMUNE RESPONSE; INHIBITION KINETICS; KIDNEY CARCINOMA; LYMPHOMA; MELANOMA B16; MOUSE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CARCINOMA; RASH; RECEPTOR UPREGULATION; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CELL DIVISION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FIBROSARCOMA; GENE EXPRESSION REGULATION; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; T-LYMPHOCYTES;

EID: 0036301503     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni0702-611     Document Type: Review

References (90)

1. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
2. The B7-CD28 superfamily
3. A new member of the immunoglobulin superfamily-CTLA-4
4. CTLA-4 is a second receptor for the B cell activation antigen B7
5. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
6. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics
7. Coexpression and functional cooperativity of CTLA-4 and CD28 on activated T lymphocytes
8. CTLA-4 can function as a negative regulator of T cell activation
9. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
10. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4
11. Superantigen responses and costimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo
12. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
13. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
14. + T cells
15. Characterization of CTLA-4 structure and expression on human T cells
16. CTLA-4 mediated inhibition of early events of T cell proliferation
17. The duration of antigenic stimulation determines the fate of naive and effector T cells
18. T cell receptor signaling precedes immunological synapse formation
19. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
20. Cytolytic T lymphocyte-associated antigen-4 and the TCRζ/CD3 complexes, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2
21. Augmentation of CTLA-4 expression by wortmannin: Involvement of lysosomal sorting properties of CTLA-4
22. + T cells
23. Secretory lysosomes
24. Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells
25. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif
26. CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells
27. Cytotoxic T lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail
28. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2
29. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression
30. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein
31. Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation
32. The specific direct interaction of helper T cells and antigen-presenting B cells. II. Reorientation of the microtubule organizing center and reorganization of the membrane-associated cytoskeleton inside the bound helper T cells
33. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement
34. T-cell regulation by CD28 and CTLA-4
35. Structural mechanisms of costimulation
36. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
37. CTLA-4 ligation blocks CD28-dependent T cell activation
38. CTLA-4 regulates cell cycle progression during a primary immune response
39. Cutting edge: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous
40. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: A paradigm reconsidered
41. + immunoregulatory T cells that control autoimmune diabetes
42. + regulatory cells that control intestinal inflammation
43. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
44. + regulatory T cells in anti-tumor therapy reveals alternative pathways for suppression of auto-reactive CTL responses
45. CTLA-4 regulates induction of anergy in vivo
46. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
47. The role of CTLA-4 in the regulation and initiation of T cell responses
48. B7-I engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28
49. + TCR-transgenic T cells: Lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase
50. + T cell responses
51. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice
52. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
53. Structural analysis of CTLA-4 function in vivo
54. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells
55. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
56. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
57. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani
58. Protective immunity to nematode infection is induced by CTLA-4 blockade
59. CTLA-4 regulates the size, function, and reactivity of a primed pool of T cells
60. T cell affinity maturation by selective expansion during infection
61. A kinetic basis for T cell receptor repertoire selection during an immune response
62. + T cells during an acute virus infection
63. The composition of a primary T cell response is largely determined by the timing of recruitment of individual T cell clones
64. T cells compete for access to antigen-bearing antigen-presenting cells
65. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance
66. + T cells in resistant mice upon infection with Leishmania major
67. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice
68. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy enhanced cell cycle progression promotes recall antigen responsiveness
69. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
70. + T cells by B7-transfected melanoma cells
71. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
72. Enhancement of antitumor immunity by CTLA-4 blockade
73. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
74. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages
75. + T cell and IL-2 dependent mechanism
76. In vivo blockade of CTLA-4 enhances the priming of responsive T-cells but fails to prevent the induction of tumor antigen-specific tolerance
77. CTLA-4 blockade synergizes with tumor-derived GM-CSF for treatment of an experimental mammary carcinoma
78. Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
79. Vaccination with irradiated tumor cells engineered to secrete GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity
80. Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA-4 blockade
81. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
82. Elucidating the autoimmune and anti-tumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy
83. + T cells in the antitumor immune response
84. CTLA-4:A negative regulator of autoimmune disease
85. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis
86. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis
87. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes
88. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice
89. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer